ZBRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Zebra Technologies is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants a clear, immediate decision. The stock has decent analyst support and bullish hedge fund activity, but the current technical setup is weak, no fresh catalyst is present, insider selling is heavy, and the stock is drifting below key pivot levels. My direct view: hold off for now rather than buy immediately.
ZBRA is in a mixed-to-bearish near-term trend. The price at 246.74 is below the pivot level of 249.404, which suggests limited immediate upside. MACD histogram is -0.246 and still expanding negatively, indicating downside momentum is building. RSI_6 at 48.03 is neutral, so the stock is not oversold enough to signal a strong entry. Moving averages are converging, which usually means trend indecision rather than a clean breakout. Support sits at 238.139 and 231.18, while resistance is at 260.67 and 267.629. The short-term pattern data also suggests weakness, with a 70% chance of -0.83% next day, -1.91% next week, and -2.5% next month.
Analyst sentiment improved meaningfully after Q1 results. Baird raised its target to $310 and upgraded to Outperform, KeyBanc upgraded to Overweight with a $305 target, and Barclays lifted its target to $345 while keeping Overweight. Citi also raised its target to $284, citing improving demand and execution. Hedge funds are buying aggressively, which supports longer-term confidence. The analysts generally view Q1 and guidance as evidence that memory cost pressure may be manageable and short-cycle demand is improving.
No news in the past week means there is no fresh event-driven catalyst supporting an immediate move higher. Insider activity is negative, with insiders selling sharply over the last month. Technically, the stock is still below pivot and momentum is negative. The recent price action and pattern analysis suggest additional downside over the short term. Also, the financial snapshot is unavailable, so there is no confirmed latest-quarter revenue or earnings trend to strengthen the buy case today.
Latest quarter financial data was not provided due to an error, so I cannot assess detailed revenue, EPS, or margin trends. The analyst notes do indicate that Q1 results were stronger than feared and that guidance improved, especially around memory costs and demand outlook. Since the latest quarter season was Q1, the market seems to have reacted positively to improving execution and guidance, but the actual financial figures are unavailable here.
Recent analyst trend is clearly improving. Baird upgraded to Outperform with a $310 target, KeyBanc upgraded to Overweight with a $305 target, and Barclays raised its target to $345 with an Overweight rating. Citi remains Neutral but still increased its target to $284. Earlier in April and March, targets were reduced, so the direction has recently shifted from cautious to more constructive. Wall Street pros are leaning bullish on execution, demand recovery, and the possibility that memory headwinds are already priced in. The main con view is that not all analysts are fully bullish, and the stock still faces cost pressure and only moderate near-term technical support.
